Drug Trial Radar · NCT04033926
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
Last checked: Nov 20, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Jan 14, 2020
Primary completion
Apr 6, 2022
Study completion Apr 6, 2022
Sponsor
- Lead sponsor
- Kezar Life Sciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with KZR-616 in patients with active polymyositis (PM) or dermatomyositis (DM). Patients were evaluated for eligibility during the Screening Period. Eligible patients were stratified by diagnosis of DM or PM and randomized 1:1 to Arm A or Arm B of the study. During the 32-week treatment period, patients received study drug subcutaneously (SC) once weekly with 2 treatment periods of 16 weeks each. This study was conducted on an outpatient basis.
Conditions
- Polymyositis
- Dermatomyositis
Interventions
KZR-616Drug
Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks
PlaceboDrug
Subcutaneous injection for 16 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in the Total Improvement Score (TIS) From Start to End of Zetomipzomib (KZR-616) Treatment PeriodTime frame: 16 weeks in each Treatment Period (32 weeks total)
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
KZR Research Site
Beverly Hills, California
KZR Research Site
Orange, California
KZR Research Site
Miami, Florida
KZR Research Site
Atlanta, Georgia
KZR Research Site
Kansas City, Kansas
KZR Research Site
Baltimore, Maryland
KZR Research Site
Ann Arbor, Michigan
KZR Research Site
Great Neck, New York
KZR Research Site
Duncansville, Pennsylvania
KZR Research Site
Pittsburgh, Pennsylvania
KZR Research Site
Austin, Texas
KZR Research Site
Henrico, Virginia
KZR Research Site
Prague, Czechia
KZR Research Site
Göttingen, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.